Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024 [5][14] - The fourth quarter of 2025 saw net product sales of $149 million, compared to $99 million in the same quarter of the previous year [14] - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The commercial cash contribution margin in 2025 was approximately 55%, a significant increase from the prior year [15] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] - The company anticipates a return to positive cash flow in 2027, following increased R&D expenses in 2026 [16] Company Strategy and Development Direction - The company is focused on advancing its pipeline with multiple clinical and regulatory milestones, including the approval of Ctexli for CTX and a tablet formulation of LIVMARLI [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address significant unmet needs in rare diseases [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a strong commercial business and a robust pipeline with four potentially pivotal readouts expected in the next 18 months [17] - The company is committed to disciplined execution and delivering impactful medicines for patients with rare diseases [9][17] Other Important Information - The company completed two private placements concurrent with the closing of the Bluejay acquisition, generating gross proceeds of $268.5 million [15] - The company is on track to report top-line data from the volixibat VISTA study in PSC in the second quarter of 2026 [10][11] Q&A Session Summary Question: Volixibat pricing strategy - Management indicated that pricing considerations for volixibat will be based on data closer to launch, noting its unique positioning due to the lack of approved medicines for PSC [19][20] Question: Risk factors in PSC trial - Management acknowledged the episodic nature of pruritus in PSC patients and emphasized the study design's focus on enrolling patients with persistent pruritus to limit variability [25][28] Question: Similarities between VISTA and VANTAGE study designs - Management highlighted commonalities in studying cholestatic pruritus and confirmed that patients with moderate to severe pruritus will be selected for both studies [35][36] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current VISTA study has a sufficient safety database and plans to interact with the FDA regarding the submission plan after top-line data [40] Question: Market for hepatitis delta virus (HDV) - Management noted the evolving landscape for HDV treatments and expressed optimism about brelovitug's potential as a best-in-class option [70][71] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to the brelovitug program, with significant investments in CMC [72]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024, exceeding guidance [4][13] - The total operating expense for 2025 was $543 million, which included R&D expenses of $186 million and SG&A expenses of $257 million [13][14] - The commercial cash contribution margin improved to approximately 55% in 2025, up from the previous year [14] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, contributing significantly to the overall sales [4] - The bile acid medicines contributed an additional $161 million to the total sales [4] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [5] - The company is entering 2026 with a strong pipeline, including four potentially registrational clinical readouts expected over the next 18 months [8] Company Strategy and Development Direction - The company is focused on disciplined execution and growth, with a strong emphasis on advancing its pipeline through clinical and regulatory milestones [5][6] - The addition of brelovitug for chronic hepatitis delta virus is seen as a strategic fit, enhancing the company's portfolio and potential revenue [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for 2026, highlighting the strong performance of the commercial business and the robust pipeline [16] - The company anticipates a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet [15] Other Important Information - The company completed two private placements generating gross proceeds of $268.5 million, which will support the acquisition and operational needs [14] - The company has received Fast Track designation from the FDA for MRM-3379 in Fragile X syndrome, indicating its potential to address significant unmet needs [12] Q&A Session Summary Question: Pricing strategy for volixibat - Management indicated that pricing considerations for volixibat will be based on data and market positioning, noting the unique opportunity in the absence of approved therapies for PSC [18][19] Question: Variability in pruritus in PSC patients - Management acknowledged the episodic nature of pruritus in PSC and emphasized the study design's focus on enrolling patients with persistent pruritus to ensure relevant data [23][27] Question: Similarities and differences in study designs for PSC - Management highlighted the commonality in studying cholestatic pruritus across different conditions, with a focus on ensuring that patients with moderate to severe pruritus are enrolled [32][34] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current study has a sufficient safety database and plans to interact with the FDA regarding submission plans after top-line data is available [38] Question: Market potential for HDV - Management discussed the evolving landscape for HDV treatments and the potential for brelovitug to set a new standard in response rates and safety profiles [68] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to brelovitug, with significant investments in manufacturing and clinical studies [70]

Core Viewpoint - Mirum Pharmaceuticals is positioned for significant growth, with its share price having more than doubled in the past year and expectations for further increases in 2026 due to key developments in its pipeline and financial performance [1]. Financial Performance - Mirum achieved positive cash flow from operations in 2025, marking a significant milestone for the company [2]. - Net product sales for Livmarli increased by 69% year over year in 2025, reaching $359 million, while sales for Cholbam and Ctexli rose by 31% to $161 million. The company anticipates overall revenue guidance of $630 million to $650 million for the current year [5]. Regulatory Approvals - The company received two FDA approvals in the previous year: Ctexli for treating cerebrotendinous xanthomatosis and a tablet formulation of Livmarli for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [3]. Pipeline Developments - On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline, which targets chronic hepatitis delta virus, a rare liver disease with no current approved treatment in the U.S. [4]. - The company is expecting results from a Phase 2B clinical study of volixibat for primary sclerosing cholangitis in the second quarter of 2026, with plans to file for accelerated approval in the second half of the year [6]. - Results from a Phase 3 study of brelovitug for HDV treatment are anticipated in the latter half of 2026, with potential filing for approval in early 2027 if results are positive [8]. - The timing of the Phase 3 study of Livmarli for pruritus in rare cholestatic conditions has been accelerated, with enrollment expected to complete in the first half of 2026 and topline data to be reported by year-end [9].

Core Insights - Mirum Pharmaceuticals is a mid-cap biotech stock that has seen significant gains, with a nearly 70% increase in 2025, and is expected to perform even better in 2026 [2][3] Company Performance - The current market capitalization of Mirum Pharmaceuticals is $4 billion, with a current stock price of $69.88 and a gross margin of 79.85% [3] - Livmarli, one of Mirum's three approved products, is the primary growth driver, with sales increasing by 56% year-over-year in Q3 2025 to $92.2 million, accounting for approximately 69% of total sales [3][4] - Combined sales for Mirum's other two bile acid medicines, Cholbam and Ctexli, rose by 31% year-over-year in Q3 to $40.8 million [6] Product Approvals and Pipeline - Livmarli was first approved by the FDA in September 2021 for treating cholestatic pruritus in patients with Alagille syndrome, a rare genetic disorder [4] - In 2024, Mirum received two additional FDA approvals for Livmarli for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in patients aged five years and older, and for a tablet version of Livmarli [5] - The company has two promising pipeline candidates, voloxibat and MRM-3379, which could also contribute significantly to future revenue [8][10] Future Outlook - The introduction of a tablet formulation of Livmarli is expected to enhance sales, with early indications of strong uptake [7] - Mirum anticipates that Livmarli could generate annual sales exceeding $1 billion [8] - Positive topline data from ongoing Phase 2 studies for voloxibat and MRM-3379 could serve as catalysts for further stock performance [9][10]

Core Insights - Mirum Pharmaceuticals reported earnings of 5 cents per share for Q3 2025, surpassing the Zacks Consensus Estimate of a loss of 10 cents, and improved from a loss of 30 cents per share in the same quarter last year [1][8] - Revenues for Q3 reached $133 million, a year-over-year increase of 47.1%, exceeding the Zacks Consensus Estimate of $132 million, driven by strong sales of Livmarli and bile acid products [2][8] Financial Performance - Livmarli's net product sales were $92 million in Q3, reflecting a 56% increase year over year, with U.S. sales at $64 million and international sales at $28 million [6][8] - Net product sales of bile acid products, including Cholbam and Ctexli, totaled $40.8 million in Q3, marking a 31% year-over-year increase [9] - Research and development expenses rose by 35.6% year over year to $43 million, while selling, general, and administrative expenses increased by 22.6% to $61.9 million [9] Guidance and Outlook - The company tightened its 2025 revenue guidance to a range of $500-$510 million, up from the previous range of $490-$510 million, with the Zacks Consensus Estimate currently at $508.9 million [11] Product Developments - Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with progressive familial intrahepatic cholestasis [3] - A new tablet formulation of Livmarli was launched in the U.S. in June 2025, aimed at providing convenience for older patients [4] - Mirum acquired Travere Therapeutics' bile acid products in August 2023, enhancing its portfolio with Cholbam and Ctexli [4] Pipeline Updates - Mirum is conducting a phase III EXPAND study for Livmarli in rare cholestatic conditions, with enrollment expected to complete in 2026 [12] - The lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis [12][13] - A phase II study on the newly in-licensed PDE4D inhibitor, MRM-3379, for Fragile X syndrome has been initiated [13] Market Performance - Mirum's shares have increased by 71.7% year to date, significantly outperforming the industry average rise of 10.9% [5]

Core Insights - Mirum Pharmaceuticals reported a narrower loss of 30 cents per share in Q1 2025, compared to a loss of 54 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 39 cents [1][2] - The company's revenues for Q1 2025 reached $111.6 million, reflecting a year-over-year increase of nearly 62%, surpassing the Zacks Consensus Estimate of $98 million [2][3] Financial Performance - Livmarli's net product sales were $73.2 million in Q1 2025, marking a 71% increase year over year, with U.S. sales at $49.5 million and ex-U.S. sales at $23.7 million [6] - Net product sales from bile acid products, including Cholbam and Ctexli, totaled $38.4 million in Q1 2025, up 47% year over year [7] - Research and development expenses rose by 42.8% year over year to $46 million, while selling, general, and administrative expenses increased by 26.5% to $57.7 million [7][8] Guidance and Future Outlook - Mirum raised its full-year revenue guidance for 2025 to a range of $435-$450 million, up from the previous estimate of $420-$435 million, due to strong demand for its commercial products [9] - The company is evaluating Livmarli in a phase III study for treating pruritus in rare cholestatic conditions, with enrollment expected to complete in 2026 [10] Recent Developments - The FDA approved a new tablet formulation of Livmarli for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis [10] - Ctexli tablets received FDA approval for treating adults with cerebrotendinous xanthomatosis, becoming the first approved treatment for this condition [11] - Mirum's lead pipeline candidate, volixibat, is in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with enrollment expected to complete in 2026 [11][12]